PROG Key Statistics, Chart & Performance
The current stock price of PROG is 0.8845 null. In the past month the price decreased by -25.67%. In the past year, price decreased by -67.48%.
PROG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.82 | 102.80B | ||
| CI | THE CIGNA GROUP | 10.12 | 76.77B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 130.5 | 24.01B | ||
| LH | LABCORP HOLDINGS INC | 16.24 | 21.30B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.17 | 19.73B | ||
| GH | GUARDANT HEALTH INC | N/A | 14.34B | ||
| DVA | DAVITA INC | 12.38 | 8.06B | ||
| HIMS | HIMS & HERS HEALTH INC | 65.04 | 8.00B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 39.14 | 7.20B | ||
| CHE | CHEMED CORP | 19.87 | 6.19B | ||
| RDNT | RADNET INC | 201.26 | 5.90B | ||
| OPCH | OPTION CARE HEALTH INC | 21.87 | 5.17B |
Related stock screener links
About PROG
Company Profile
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
Company Info
BIORA THERAPEUTICS INC
4330 La Jolla Village Drive, Suite 200
San Diego CALIFORNIA 92122 US
CEO: Harry Stylli
Employees: 124
Phone: 18552932639.0
BIORA THERAPEUTICS INC / PROG FAQ
What does BIORA THERAPEUTICS INC do?
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
What is the stock price of BIORA THERAPEUTICS INC today?
The current stock price of PROG is 0.8845 null. The price decreased by -3.47% in the last trading session.
Does BIORA THERAPEUTICS INC pay dividends?
PROG does not pay a dividend.
How is the ChartMill rating for BIORA THERAPEUTICS INC?
PROG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is BIORA THERAPEUTICS INC (PROG) stock traded?
PROG stock is listed on the Nasdaq exchange.
How is the market expecting PROG stock to perform?
7 analysts have analysed PROG and the average price target is 4.08 null. This implies a price increase of 361.28% is expected in the next year compared to the current price of 0.8845.
PROG Technical Analysis
PROG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PROG. PROG has a bad profitability rating. Also its financial health evaluation is rather negative.
PROG Financial Highlights
Over the last trailing twelve months PROG reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 68.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -966.06% | ||
| ROA | -227.32% | ||
| ROE | N/A | ||
| Debt/Equity | -1.49 |
PROG Forecast & Estimates
7 analysts have analysed PROG and the average price target is 4.08 null. This implies a price increase of 361.28% is expected in the next year compared to the current price of 0.8845.
For the next year, analysts expect an EPS growth of 77.59% and a revenue growth -100% for PROG